Athena Feminine Technologies

XOMA is a pioneer and leader in the discovery, development and manufacture of therapeutic antibodies, with a therapeutic focus that includes cancer and immune diseases. The company has a royalty interest in RAPTIVA, a monoclonal antibody product marketed worldwide to treat moderate-to-severe plaque psoriasis. Its discovery and development capabilities include antibody phage display, bacterial cell expression, and human engineering technologies, plus a fully integrated drug development infrastructure. XOMA s development collaborators include Aphton Corporation, Chiron Corporation and Lexicon Genetics Incorporated. The company pipeline also includes proprietary programs in preclinical and clinical development. It trades on NASDAQ under the symbol XOMA. The company is headquartered in Berkeley, Calif.

Fresenius Medical Care in Concord, CA is dedicated to providing comprehensive solutions for individuals living with chronic kidney disease and related conditions. Through personalized patient care, innovative products, and ongoing research, they strive to improve the quality of life for every patient every day. With a focus on dialysis services, vascular care, renal pharmacy, and laboratory services, Fresenius Medical Care is committed to transforming healthcare through compassion, innovation, and evidence-based insights. Their global presence and dedication to advancing clinical and scientific strategies demonstrate their ongoing commitment to enhancing patient care worldwide. Generated from the website

OXIS International develops technologies and products used for the research, diagnosis, treatment and prevention of diseases caused by the oxidative stress associated with damage from free radical and reactive oxygen species. The company offers more than 80 research products that are used in testing for oxidative, antioxidant, nitrosative and inflammatory biomarkers, which are thought to play a central role in many human degenerative diseases, including cancer, diabetes, atherosclerosis, stroke, Alzheimer disease, Parkinson disease and amyotrophic lateral sclerosis. The company holds the rights to three therapeutic classes of compounds in the area of oxidative stress and has focused commercialization programs in clinical cardiovascular markers, including myeloperoxidase and glutathione peroxidase, as well as a highly potent antioxidant, ergothioneine. OXIS International is headquartered in Portland, Ore.